TY - JOUR
T1 - Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test
AU - Wang, Qiao
AU - Feng, Lili
AU - Zhang, Haohai
AU - Gao, Juehua
AU - Mao, Changchuin
AU - Landesman-Bollag, Esther
AU - Mostoslavsky, Gustavo
AU - Lunderberg, Justin M.
AU - Zheng, Weina
AU - Hao, Shushun
AU - Gao, Wenda
N1 - Funding Information:
This study was supported by Massachusetts Life Science Center's Accelerating Coronavirus Testing Solutions (ACTS) grant awarded to Antagen Diagnostics, Inc.
Publisher Copyright:
© 2022 The Author(s).
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Although mRNA vaccines against SARS-CoV-2 were highly efficacious against severe illness and hospitalization, they seem to be less effective in preventing infection months after vaccination, especially with the Delta variant. Breakthrough infections might be due to higher infectivity of the variants, relaxed protective measures by the general public in "COVID-19 fatigue", and/or waning immunity post-vaccination. Determining the neutralizing antibody levels in a longitudinal manner may address this issue, but technical complexity of classic assays precludes easy detection and quick answers. We developed a lateral flow immunoassay NeutraXpress™ (commercial name of the test kit by Antagen Diagnostics, Inc.) and tested fingertip blood samples of subjects receiving either Moderna or Pfizer vaccines at various time points. With this device, we confirmed the reported clinical findings that mRNA vaccine-induced neutralizing antibodies quickly wane after 3-6 months. Thus, using rapid tests to monitor neutralizing antibody status could help identify individuals at risk, prevent breakthrough infections, and guide social behavior to curtail the spread of COVID-19.
AB - Although mRNA vaccines against SARS-CoV-2 were highly efficacious against severe illness and hospitalization, they seem to be less effective in preventing infection months after vaccination, especially with the Delta variant. Breakthrough infections might be due to higher infectivity of the variants, relaxed protective measures by the general public in "COVID-19 fatigue", and/or waning immunity post-vaccination. Determining the neutralizing antibody levels in a longitudinal manner may address this issue, but technical complexity of classic assays precludes easy detection and quick answers. We developed a lateral flow immunoassay NeutraXpress™ (commercial name of the test kit by Antagen Diagnostics, Inc.) and tested fingertip blood samples of subjects receiving either Moderna or Pfizer vaccines at various time points. With this device, we confirmed the reported clinical findings that mRNA vaccine-induced neutralizing antibodies quickly wane after 3-6 months. Thus, using rapid tests to monitor neutralizing antibody status could help identify individuals at risk, prevent breakthrough infections, and guide social behavior to curtail the spread of COVID-19.
KW - LFIA
KW - SARS-CoV-2
KW - mRNA vaccine
KW - neutralizing antibody
KW - rapid test
UR - http://www.scopus.com/inward/record.url?scp=85125280475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125280475&partnerID=8YFLogxK
U2 - 10.1093/abt/tbac004
DO - 10.1093/abt/tbac004
M3 - Article
C2 - 35146332
AN - SCOPUS:85125280475
SN - 2516-4236
VL - 5
SP - 55
EP - 62
JO - Antibody Therapeutics
JF - Antibody Therapeutics
IS - 1
ER -
